NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) reported Tuesday that its sales in the second quarter rose 1.9 percent to $18.8 billion, in part a reflection of sales growth within its medical devices business segment (specifically the cardiovascular business and the Acuvue contact lens product line). Adjusted net earnings totaled $5.0 billion in the quarter, representing an increase of 3.1 percent. Both sales and earnings results are compared to the same period in 2016.

Operational sales results increased 2.9 percent, with the negative impact of currency at 1 percent, according to J&J’s announcement. Domestic sales increased 1.6 percent in the quarter.

“Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year,” J&J chairman and chief executive officer Alex Gorsky said in a statement. With its results, J&J also raised its sales and adjusted earnings guidance for the full-year 2017.

“Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business, Acuvue contact lenses in the Vision Care business, and Advanced Surgery products, partially offset by declines in the Diabetes Care business,” the J&J statement noted.

In the Vision Care segment, U.S. sales rose 63.3 percent to $405 million in the second quarter, while international sales increased 48.7 percent to $650 million, according to J&J’s statement. J&J noted that “sales included the impact of the first full quarter of the recently completed acquisition of Abbott Medical Optics, which contributed 5.1 percent to worldwide operational sales growth.”

Sales in the contact lens category climbed 10.5 percent to $274 million in the U.S. market during the second quarter, while international contact lens sales increased 9.6 percent to $479 million. In the first half of fiscal 2017, J&J reported that its U.S. contact lens business has increased 8.2 percent to $530 million.